Prostate cancer Posts - Page 8 of 80 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Posted by on Apr 18, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed and evaluated which hormonal therapy should be given first, abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) or enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that AAP followed by ENZ is more effective in delaying...

Read More

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Comparing the activity and safety of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Apr 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of lutetium-177 [177Lu]-PSMA-617 (177LuPSMA) versus cabazitaxel (Jevtana) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 177LuPSMA treatment showed a higher response with fewer side effects in these patients. Some...

Read More

Comparing the safety outcomes between proton beam therapy vs intensity-modulated radiation therapy in early stage prostate cancer

Comparing the safety outcomes between proton beam therapy vs intensity-modulated radiation therapy in early stage prostate cancer

Posted by on Mar 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the safety outcomes between moderately-hypofractionated intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) in patients with early-stage prostate cancer. The data showed that both treatments were safe and well-tolerated. Some background Radiation therapy (RT) is a treatment used for low- or...

Read More

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Posted by on Mar 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo. Some...

Read More

Evaluating photoselective vaporization for urinary symptoms in patients with prostate cancer on active surveillance.

Evaluating photoselective vaporization for urinary symptoms in patients with prostate cancer on active surveillance.

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients with prostate cancer with lower urinary tract symptoms (LUTS) during active surveillance. The results suggested that PVP treatment was safe and effective in these patients. Some background Active surveillance (AS)...

Read More

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of phosphodiesterase-5 (PDE5) inhibitor tadalafil (Cialis) for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) after low-dose-rate (LDR) brachytherapy (BT) in patients with localized prostate cancer. The data showed that tadalafil improved the LUTS and ED outcomes...

Read More

Urinary, sexual outcomes and tumor control after robot-assisted laparoscopic radical prostatectomy in localized prostate cancer

Urinary, sexual outcomes and tumor control after robot-assisted laparoscopic radical prostatectomy in localized prostate cancer

Posted by on Mar 14, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the urinary, sexual, and tumor control outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) over time in patients with localized prostate cancer. The study found that analyzing these three outcomes is beneficial for these patients. Some background Localized prostate cancer (PCa) is a form of...

Read More

Searching for patients with confined prostate cancer to trial a cryoablation procedure

Searching for patients with confined prostate cancer to trial a cryoablation procedure

Posted by on Mar 13, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is looking to examine the use of a new treatment software (UroNAV Ablation) system in treating confined prostate cancer with cryoablation. The main outcomes to be measured will be device/treatment-related complications and tumor control. This trial is being carried out in New York, US.  The details Localized...

Read More

Comparing outcome in robotic-assisted versus laparoscopic prostate surgery

Comparing outcome in robotic-assisted versus laparoscopic prostate surgery

Posted by on Mar 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of functional and oncological outcomes of robotic-assisted (RA) and laparoscopic (Lap) radical prostatectomy (RP; removal of the prostate) in localized and locally advanced prostate cancer (PCa). the study concluded that RARP was similarly effective and had better urinary and sexual outcomes...

Read More

Evaluating the outcomes of salvage Retzius-sparing robotic-assisted radical prostatectomy

Evaluating the outcomes of salvage Retzius-sparing robotic-assisted radical prostatectomy

Posted by on Mar 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and functional outcomes of using the Retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) as a salvage treatment for patients with localized prostate cancer (PCa). The study found that the sRS-RARP approach was associated with good urinary and oncological outcomes in these...

Read More